Welcome to our dedicated page for High Tide SEC filings (Ticker: HITI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
High Tide Inc. filings document its disclosures as a Canadian foreign issuer operating in cannabis retail, e-commerce accessories, hemp-derived CBD and international medical cannabis distribution. Form 6-K reports furnish company news releases covering Canna Cabana store activity, operating and financial results, subsidiary developments, insider share purchases, common-share trading matters, and financing arrangements.
The filing record also includes governance and compensation materials, including an amended statement of executive compensation. High Tide disclosures address its common-share capital structure, senior credit arrangements, executive and director compensation, board and management oversight, ownership information, material events, and risk-related topics connected to regulated cannabis markets in Canada, the United States and Germany.
High Tide Inc. is expanding its retail footprint with a new Canna Cabana cannabis store in Toronto’s Rexdale neighbourhood. The store at 150 Silver Reign Drive is expected to begin selling recreational cannabis and accessories for adult use on May 17, 2026.
This opening brings Canna Cabana’s footprint to 222 stores across Canada, including 98 locations in Ontario. Management highlights the site’s position in a busy power centre serving more than 263,000 residents within five kilometres, and frames the move as part of a disciplined, profitability-focused growth strategy in Canada’s largest cannabis market.
High Tide Inc. reported that certain officers, directors and consultants, led by its President and CEO, bought a total of 90,882 common shares on the open market between May 6 and May 8, 2026, at an average price of $3.39 per share. Following these purchases, insiders and certain consultants together own or control 7,720,360 common shares, representing about 8.8% of issued and outstanding shares. Management linked the buying to confidence in the company’s growth prospects, highlighting a $40 million senior lending credit facility term sheet with a Big 5 Canadian bank, record quarterly medical cannabis distribution volumes at Remexian, and Remexian’s German market share rising to over 14%.
High Tide Inc. reported that its 51%-owned German subsidiary, Remexian Pharma GmbH, sold 7.6 tonnes of medical cannabis into the German market in the quarter ended April 30, 2026, the highest quarterly distribution volume in its history.
The tonnage grew 21% sequentially and 49% year over year, supporting the company’s view that Germany is a key growth market and a platform for broader European expansion. Management links this performance to combining Remexian’s German distribution platform with High Tide’s Canadian procurement scale.
The company emphasized that these tonnage figures are preliminary and unaudited, may be revised when full second fiscal quarter 2026 financial statements are prepared, and should not replace the complete results, which are expected to be reported in June 2026.
High Tide Inc. has signed a term sheet with one of Canada's Big 5 chartered banks for new senior secured credit facilities totaling $40 million. The package includes a $25 million revolving facility with a three-year term and a $15 million delayed draw term loan with seven-year amortization.
On closing, the revolver is expected to refinance a little over $6 million owed to connectFirst Credit Union, leaving almost $19 million of additional revolver capacity. The delayed draw term loan is intended to refinance existing $15 million second-lien debentures. Interest will range between Prime + 2% and Prime + 3%, depending on leverage, with financial covenants tied to debt-to-EBITDA and fixed charge coverage tests. Closing is expected within 60 days, subject to customary conditions.
High Tide Inc. filed an amended statement of executive compensation for the year ended October 31, 2025, correcting omissions and errors in its prior disclosure and updating finalized annual incentive payouts.
The filing details the company’s pay philosophy, use of a cannabis‑sector peer group, and a three-part program of salary, discretionary cash bonuses, and long-term equity under a 20% fixed Omnibus Plan. In 2025, CEO Harkirat (Raj) Grover received salary of $825,000, a bonus of $1,056,000 and share-based awards of $1,540,111, for total compensation of $3,382,845. Across executives and directors, 708,164 RSUs were granted, and outstanding options and RSUs feature broad change-of-control vesting and severance protections.
High Tide Inc. is responding to investor concerns about unusual trading in its common shares. The company says it has observed, over more than ten consecutive quarters, that its strong earnings results often spark positive after-hours reactions, yet the next regular-session closing price frequently falls below the prior close.
Management and the board, working with the company’s market maker, have been reviewing trading data and now believe some activity may not reflect normal market forces and may be contrary to securities laws. High Tide plans to hire forensic investigators and trading‑surveillance specialists to review trading around earnings and other material news, and expects to share their findings with Canadian and U.S. regulators.
The company invites shareholders and market participants with relevant information to contact its investor relations team. High Tide highlights its cannabis retail and medical operations, including 221 Canna Cabana locations and a 12% share of the Canadian market, along with its German medical cannabis distributor Remexian Pharma.
High Tide Inc. filed a Form 6-K highlighting the opening of a new Canna Cabana retail cannabis store in Caledonia, Ontario. The store at 345 Argyle Street South began selling recreational cannabis and accessories for adult use on April 20, 2026, bringing the Canna Cabana network to 221 locations across Canada, including 97 in Ontario.
The Caledonia store is located at the south end of town in a busy commercial node alongside a pharmacy, liquor store, and national retailers, targeting a growing trade area with strong household incomes. CEO Raj Grover framed the 4/20 opening as a symbolic milestone as the brand approaches eight years since its first Canna Cabana store, positioning the launch as part of a disciplined national scaling strategy.
High Tide Inc. filed a Form 6-K announcing that its senior executives and advisors will speak on panels at multiple cannabis and investor conferences across North America and Europe from April to June 2026.
The company describes itself as a leading retail-forward cannabis enterprise, with its Canna Cabana chain operating 220 Canadian stores and 1 international location and holding a 12% share of the Canadian market. Its German subsidiary, Remexian Pharma GmbH, is licensed to import medical cannabis from 19 countries.
High Tide Inc. reports that its U.S. hemp-derived CBD subsidiary, NuLeaf Naturals, is pursuing participation in the U.S. Centers for Medicare & Medicaid Services Innovation Center’s Beneficiary Engagement Incentive pilot program. The pilot, launching April 1, 2026, allows certain Medicare model participants to furnish eligible hemp-derived CBD products to beneficiaries at no cost, up to US$500 per year per beneficiary, with costs borne by participating organizations.
NuLeaf Naturals, founded in 2014 and operating cGMP-certified, FDA-registered facilities, believes its THC-free and broad-spectrum CBD products align with the program’s compliance requirements. High Tide views this pilot as a potential growth driver for its U.S. CBD business while continuing advocacy through the National Compassionate Care Council.
High Tide Inc. reported strong first fiscal quarter 2026 results, with revenue of $178,329 thousand, up 25% from $142,461 thousand a year earlier. Gross profit also rose 25% to $44,409 thousand, keeping gross margin steady at 25%, showing the business is growing while maintaining pricing and cost discipline.
Adjusted EBITDA improved to $11,457 thousand, a 62% increase from $7,089 thousand, and Adjusted EBITDA margin edged up to 6%. Net loss narrowed significantly to $352 thousand from $2,689 thousand, and basic and diluted income (loss) per share improved to $0.01 from $(0.03).
Cash generation improved meaningfully. Net cash provided by operating activities was $5,860 thousand versus $683 thousand, and free cash flow swung to a positive $2,939 thousand from negative $1,900 thousand. Management highlighted record revenue exceeding $700 million annualized, continued expansion of Canna Cabana’s 220-store Canadian network, growing German medical cannabis sales through Remexian, and recovering U.S. e-commerce trends.